MedPath logo

CILOXAN STERILE OPHTHALMIC OINTMENT 3 mg/g

Prescription Only
Drug type: Therapeutic
ATC code: S01AX13
Dosage form: OINTMENT
Route of administration: OPHTHALMIC
Active ingredient: CIPROFLOXACIN HCl EQV CIPROFLOXACIN; CIPROFLOXACIN HCL EQV CIPROFLOXACIN

3 Indications

Ocular Use:

  • Ciloxan Eye Ointment is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial.

    Ciloxan Eye Ointment is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below:

    Gram-Positive:

    Staphylococcus aureus

    Staphylococcus epidermidis

    Streptococcus pneumoniae

    Streptococcus Viridans Group

    Gram-Negative:

    Haemophilus influenza

5 Contraindications

Hypersensitivity to the active substance, or to other quinolones or to any of the excipients.

4 Dosage regimen and administration

Dosage Regimen

Apply a 1/2” ointment ribbon into the conjunctival sac 3 times a day on the first 2 days, then apply a 1/2” ointment ribbon 2 times a day for the next 5 days.

Special populations

Renal and hepatic Impairment

No studies have been performed in patients with renal or hepatic impairment.

Pediatric patients

Safety and effectiveness of CILOXAN Eye Ointment in pediatric patients below the age of two years have not been established.

Geriatric patients (65 years of age or above)

No dosage regimen adjustments is required in patients 65 years of age or above.

Method of administration

Ciloxan Eye ointment

  • For ocular use only
  • After cap is removed, if tamper evident snap collar is loose, it should be removed before using the product.
  • To avoid contamination, the tip of the tube should not touch any surface and should also not come into contact with the eye as this may cause injury to the eye. Keep the tube tightly closed when not in use.
  • Either nasolacrimal occlusion or gently closing the eyelid(s) after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.
  • Patients should be advised not to wear contact lenses during treatment with CILOXAN eye ointment. Patients should remove contact lenses prior to application and wait at least 15 minutes before reinsertion.
  • If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.
Registrant
NOVARTIS (SINGAPORE) PTE LTD
Approval Date
2000-01-28
Approval Number
SIN11265P
Manufacturer
s.a. ALCON-COUVREUR n.v
Licence Holder
NOVARTIS (SINGAPORE) PTE LTD